A signal to BIG PHARMA/Government that ENZC has the goods to lock down the Coronavirus.
Now the ball is in BIG PHARMA/Government court and the question is "who is gonna pay ball with ENZC?
ENZC possess a must have solution.
This is not a situation of keep the small company down.
This is a situation is how quickly can we get this on the street and "we" is not just ENZC. Now that this information is in the news feeds, people in "high places" will have to step in and get this moving like at warp speed haha.
Seriously though if those in power don't get this moving and there is a bad turn with the coronavirus shame on them. They know the current therapeutics are limited.
The information in the press release says it all:
The Company has always emphasized the need for therapeutics that target conserved and expectedly immutable virus sites - whether the therapeutics is a monoclonal antibody or a preventative vaccine. There is agreement among experts that multiple neutralizing antibodies is critical to effective control of viruses such as the Coronavirus. Recognizing this necessity, if a site is 99% conserved (exits in all 99% of the 50,512 Coronavirus isolates curated), then it can be expected that the next 50,512 variations will also contain the conserved sites. Targeting these conserved sites allows the production of a therapeutic that will not become ineffective due to mutation of the virus. In other words, even a "variant form of the virus" will expectedly contain the immutable targeted sites. Targeting those immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site that has mutated.
Variant have arisen in viruses other that the Coronavirus. Prior government funding in producing anti-HIV monoclonal antibodies have failed due to what the industry calls "virus escape". The anti-HIV monoclonal antibodies VRC01 and VRC02 produced by Vaccine Research Center in conjunction with the NIH were tested for years and then abandoned due to "virus escape". The Company's focus is on producing monoclonal antibodies that target immutable sites to avoid "virus escape".
